http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
| My Groups | biotech-news Main Page | |
Frost & Sullivan Lauds AlgoNomics' Technology Innovation
Frost & Sullivan presents the 2006 Technology Innovation Award in
the field of structural bioinformatics for drug discovery to Belgium-
based AlgoNomics NV for its pioneering Epibase(R) technology
platform. Offering an innovative and efficient method of identifying
T-cell epitopes, this platform has the potential to challenge
current sequence-based methodologies.
"A platform for T-cell epitope identification, Epibase(R) analyses
whether therapeutic protein leads show an increased risk for
immunogenicity and helps researchers optimise protein leads," say
Frost & Sullivan Research Analysts Ravi Shankar and Srimathy
Raghuraman. "In other words, AlgoNomics' technology helps
researchers avoid lengthy, expensive and overlapping peptide
studies."
An in silico platform, Epibase(R) assists the drug development
process at different stages. Researchers use this technology to
compare the immunogenecity of drug leads where they compare the T-
cell epitope content of large numbers of protein variants entering
the drug development stage. By identifying the T-cell epitopes at
the research level, certain drug leads can be rejected during the
early stages of drug development. This facilitates the selection of
the most promising protein leads and also helps in the removal of
the epitopes while optimising the proteins.
In cases where HLA alleles are linked with diseases, Epibase(R)
enables the exploration of drug candidates to check if they are safe
for the targeted patient population. It identifies new T-cell
epitopes based on structural bioinformatics and covers a broad range
of HLA subtypes, such as the CTL and humoral responses. Further, it
is also able to produce a high throughput on computer clusters.
Moreover, Epibase(R) does not rely on public databases as did
earlier tools such as Bimas, Tepitope, Epimatrix or Propred.
http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
"Vis-à-vis peptide synthesis and HLA presentation experiments,
Epibase(R) performs much faster screening and provides more cost-
effective information delivery," note Mr. Shankar and Ms.
Raghuraman. "More importantly, Epibase(R) helps researchers avoid
lengthy, expensive overlapping peptide studies, which translates
into cost reductions of over 100.000 euro per protein analysed, and
a gain in speed of two weeks when compared to the typical three to
six months needed for traditional tests.
AlgoNomics' focus on structural bioinformatics R&D - which yielded
this groundbreaking technology platform - will continue, with the
company working on HLA subtypes with impact in countries such as
China, India, Indonesia, and Japan, as well as the Hispanic and
Black-American population groups.
AlgoNomics collaborates with a wide range of companies such as
Cambridge Antibody Technologies, Genmab, GSK, Evogenix, J&J Tibotec,
Innogenetics, Ablynx, Bayer Cropscience, and Evolutec.
The Frost & Sullivan Award for Technology Innovation is presented
each year to the company (or individual) that has carried out new
research, which has resulted in innovation(s) that have or are
expected to bring significant contributions to the industry in terms
of adoption, change and competitive posture.
Frost & Sullivan Best Practices Awards recognise companies in a
variety of regional and global markets for demonstrating outstanding
achievement and superior performance in areas such as leadership,
technological innovation, customer service, and strategic product
development. Industry analysts compare market participants and
measure performance through in-depth interviews, analysis, and
extensive secondary research in order to identify best practices in
the industry.
About AlgoNomics
AlgoNomics is a Belgium based biotech company that provides
structural bioinformatics services to develop rationally designed
therapeutics in the broad field of immunotherapy. AlgoNomics offers
in silico support to companies that develop rationally designed
vaccines and therapeutic proteins.
AlgoNomics owns a rich, proprietary platform for structure-based
protein and peptide design. The technology platform contains
biologically validated, innovative tools, which have been developed
in-house. AlgoNomics' premier product is the Epibase(R) platform for
T-cell epitope identification in different population groups.
For more information about AlgoNomics and Epibase(R) visit
www.algonomics.com or contact
AlgoNomics N.V.
ir. Philippe Stas
Chief Operating Officer
Technologiepark 4
B-9052 Gent - Belgium
Tel.: +32-(0)9-241-11-00
Fax.: +32-(0)9-241-11-02
[EMAIL PROTECTED]
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been
partnering with clients to support the development of innovative
strategies for more than 40 years. The company's industry expertise
integrates growth consulting, growth partnership services and
corporate management training to identify and develop opportunities.
Frost & Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community, by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics. For more information,
visit www.frost.com or contact
Frost & Sullivan
Kristina Menzefricke
Promotions Manager, Best Practices - EMEA
+44-(0)-207-343-8376
[EMAIL PROTECTED]
YAHOO! GROUPS LINKS
[EMAIL PROTECTED]
